Naim, Mohd. Javed et al. published their research in Bioorganic Chemistry in 2017 |CAS: 36640-53-6

The Article related to thiazolidinedione amide derivative synthesis sar antidiabetic pharmacokinetics toxicity, antidiabetic, molecular docking, pparγ, thiazolidinedione, Pharmacology: Structure-Activity and other aspects.SDS of cas: 36640-53-6

On August 31, 2017, Naim, Mohd. Javed; Alam, Jahangir Md.; Nawaz, Farah; Naidu, V. G. M.; Aaghaz, Shams; Sahu, Meeta; Siddiqui, Nadeem; Alam, Ozair published an article.SDS of cas: 36640-53-6 The title of the article was Synthesis, molecular docking and anti-diabetic evaluation of 2,4-thiazolidinedione based amide derivatives. And the article contained the following:

A series of thiazolidinedione based amide derivatives were designed, synthesized and docked against the PPARγ receptor target. 11 Compounds from the series with good glide scores were selected for in vivo antidiabetic study based on streptozotocin induced diabetic rat model. It was observed that 4 compounds (I, II, III & IV) showed significantly good antidiabetic activity in comparison to rosiglitazone and pioglitazone as reference drugs. Compound I appeared as the most potent derivative in lowering blood glucose level and showed excellent interaction with SER 342, ILE 281, pi-pi interaction with ARG 288 and halogen bond interaction with LYS 367. Further, PPARγ transactivation and gene expression studies of compound I were carried out to investigate the possible mechanism of action through PPARγ modulation. Compound I exhibited 53.65% transactivation and elevated PPARγ gene expression by 2.1 folds. The biochem. parameters (AST, ALT and ALP levels) were found within the range with no noteworthy damage to liver. The experimental process involved the reaction of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde(cas: 36640-53-6).SDS of cas: 36640-53-6

The Article related to thiazolidinedione amide derivative synthesis sar antidiabetic pharmacokinetics toxicity, antidiabetic, molecular docking, pparγ, thiazolidinedione, Pharmacology: Structure-Activity and other aspects.SDS of cas: 36640-53-6

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Naim, Mohd. Javed et al. published their research in Archiv der Pharmazie (Weinheim, Germany) in 2018 |CAS: 36640-53-6

The Article related to pyrazole thiazolidinedione preparation ppar gamma modulator docking antidiabetic diabetes, ppar-γ, diabetes, molecular docking, thiazolidinedione, Pharmacology: Structure-Activity and other aspects.Recommanded Product: 36640-53-6

On April 3, 2018, Naim, Mohd. Javed; Alam, Ozair; Alam, Jahangir Md.; Shaquiquzzaman, Mohammad; Alam, Mumtaz Md.; Naidu, Vegi Ganga Modi published an article.Recommanded Product: 36640-53-6 The title of the article was Synthesis, docking, in vitro and in vivo antidiabetic activity of pyrazole-based 2,4-thiazolidinedione derivatives as PPAR-γ modulators. And the article contained the following:

The design, synthesis, structure-activity relationship, and biol. activity of 2,4-thiazolidinedione derivatives as peroxisome proliferator-activated receptor-γ (PPAR-γ) modulators for antidiabetic activity are reported. Fifteen 2,4-thiazolidinedione derivatives clubbed with pyrazole moiety were docked into the ligand binding domain of PPAR-γ by the Glide XP module of Schrodinger. Eight derivatives (5a (5-((3-(3,4-dichlorophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)thiazolidine-2,4-dione), 5b (5-((1-phenyl-3-(thien-2-yl)-1H-pyrazol-4-yl)methylene)thiazolidine-2,4-dione), 5d, 5f, 5i, 5l, 5n, 5o) having Glide XP scores > -8 as compared to the standard drug, rosiglitazone (Glide XP score = -9.165), showed almost similar interaction with the amino acids such as HIS 449, TYR 473, TYR 327, HIS 323, and SER 289 in the mol. docking studies. These eight derivatives were further screened for PPAR-γ transactivation and in vivo blood glucose lowering activity in the streptozotocin-induced diabetic rat model. Compounds 5o, 5n, 5a, 5i, and 5b showed 52.06, 51.30, 48.65, 43.13, and 40.36% PPAR-γ transactivation as compared to the reference drugs rosiglitazone and pioglitazone with 85.30 and 65.22% transactivation, resp. The data anal. showed significant blood glucose lowering effects (hypoglycemia) of compounds 5o, 5n, and 5a (140.1±4.36, 141.4±6.15, and 150.7±4.15, resp.), along with reference drugs pioglitazone (135.2±4.91) and rosiglitazone (141.1±5.88) as compared to the diabetic control. Furthermore, the most potent compound 5o also elevated the PPAR-γ gene expression by 2.35-fold as compared to rosiglitazone (1.27-fold) and pioglitazone (1.6-fold). It also significantly lowered the AST, ALT, and ALP levels and caused no damage to the liver. The experimental process involved the reaction of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde(cas: 36640-53-6).Recommanded Product: 36640-53-6

The Article related to pyrazole thiazolidinedione preparation ppar gamma modulator docking antidiabetic diabetes, ppar-γ, diabetes, molecular docking, thiazolidinedione, Pharmacology: Structure-Activity and other aspects.Recommanded Product: 36640-53-6

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Kamal, Raj et al. published their research in Archiv der Pharmazie (Weinheim, Germany) in 2017 |CAS: 36640-53-6

The Article related to screening triazolopyrimidine pyrazole apoptosis inducer, cytotoxic activity, pyrazole, synthesis, triazole, Pharmacology: Structure-Activity and other aspects.HPLC of Formula: 36640-53-6

Kamal, Raj; Kumar, Vipan; Kumar, Ravinder; Bhardwaj, Jitender K.; Saraf, Priyanka; Kumari, Priya; Bhardwaj, Vikas published an article in 2017, the title of the article was Design, Synthesis, and Screening of Triazolopyrimidine-Pyrazole Hybrids as Potent Apoptotic Inducers.HPLC of Formula: 36640-53-6 And the article contains the following content:

An efficient synthesis of novel 3-(3-aryl-1-phenyl-1H-pyrazol-4-yl)-5,7-dimethyl-[1,2,4]triazolo[4,3-a]-pyrimidines was accomplished by the oxidation of pyrimidinylhydrazones by using organoiodine(III) reagent. All new triazolopyrimidine derivatives bearing the pyrazole scaffold were screened to evaluate them as a reproductive toxicant in the testicular germ cells of goat (Capra hircus). This study aimed at assessing the cytol. and biochem. changes in testicular germ cells after the exposure to triazolopyrimidines in a dose- and time-dependent manner. Histomorphol. anal., fluorescence assays, apoptosis quantification, and terminal deoxynucleotidyl transferase dUTP-mediated nick-end labeling (TUNEL) assays were performed to determine cytol. changes, whereas thiobarbituric acid-reactive substance (TBARS) and ferric reducing antioxidant power (FRAP) assays were carried out to measure the oxidative stress in triazolopyrimidines treated germ cells. The parallel use of these methods enabled us to determine the role of triazolopyrimidines in inducing apoptosis as a consequence of cytogenetic damage and oxidative stress generated in testicular germ cells of goat. The experimental process involved the reaction of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde(cas: 36640-53-6).HPLC of Formula: 36640-53-6

The Article related to screening triazolopyrimidine pyrazole apoptosis inducer, cytotoxic activity, pyrazole, synthesis, triazole, Pharmacology: Structure-Activity and other aspects.HPLC of Formula: 36640-53-6

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Ashok, Dongamanti et al. published their research in Journal of the Serbian Chemical Society in 2019 |CAS: 36640-53-6

The Article related to pyrazole pyrazoline derivative microwave irradiation conventional heating antimicrobial, Pharmaceuticals: Drug Standards and other aspects.Quality Control of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde

Ashok, Dongamanti; Kavitha, Rangu; Gundu, Srinivas; Sarasija, Madderla published an article in 2019, the title of the article was Microwave-assisted synthesis and antimicrobial evaluation of 6-[3-aryl-1-phenyl-4′,5′-dihydro[4,5′-bi-1H-pyrazol]-3′-yl]–2H-chromen-5-ols.Quality Control of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde And the article contains the following content:

A new series of 6-[3-aryl-1-phenyl-4′,5′-dihydro[4,5′-bi-1H-pyrazol]-3′- -yl]-2H-chromen-5-ol derivatives was synthesized by Michael addition of chal- cones 5a-j with hydrazine hydrate in presence of sodium acetate under con- ventional heating and microwave irradiation Structural assignment of the products was confirmed based on IR, 1H-NMR, 13C-NMR, MS and anal. data. All the synthesized compounds 6a-j were screened for their antimicrobial activity against various bacterial and fungal strains. Most of the compounds exhibited variable range of antimicrobial activity and compounds 6c-f and 6i showed promising antimicrobial potency. The experimental process involved the reaction of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde(cas: 36640-53-6).Quality Control of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde

The Article related to pyrazole pyrazoline derivative microwave irradiation conventional heating antimicrobial, Pharmaceuticals: Drug Standards and other aspects.Quality Control of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Robins, Roland K. et al. published their research in Journal of the American Chemical Society in 1956 |CAS: 85426-79-5

4-Chloro-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine(cas:85426-79-5) belongs to pyrazoles-derivatives. The use of pyrazole derivatives is based on their analgesic, anti-inflammatory, antipyretic, antiarrhythmic, sedative, muscle relaxant, neuroleptic, anticonvulsant, monoamine oxidase inhibitory, antidiabetic and antibacterial activities.Safety of 4-Chloro-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine

Robins, Roland K. published an article in 1956, the title of the article was Potential purine antagonists. I. Synthesis of some 4,6-substituted pyrazolo[3,4-d]pyrimidines.Safety of 4-Chloro-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine And the article contains the following content:

EtOCH2CH(CN)2 (150 g.) added in 3-5-g. portions to 100 g. 85% N2H4.H2O with slight cooling, the mixture heated 1 hr. on the steam bath, diluted with 100 cc. H2O, and refrigerated overnight, the mushy solution filtered, and the solid washed with cold H2O yielded 97 g. 3-amino-4-cyanopyrazole (I), m. 174-5° (from H2O). I (0.5 g.) refluxed 8 hrs. with 100 cc. AcCl and evaporated to dryness on the steam bath, and the residue dissolved in 25 cc. boiling H2O, neutralized with NH4OH, and cooled gave 0.4 g. Ac derivative of I, m. 221-2° (from H2O). Finely powd. I (50 g.) added with stirring below 40° to 170 cc. concentrated H2SO4 (cooled to 20°) during 0.5 hr., and the solution stirred 1 hr. at room temperature, poured with stirring into 500 cc. H2O and 250 cc. ice, refrigerated overnight, and filtered yielded 67.0 g. 3-amino-4-pyrazolecarboxamide-0.5H2SO4 (II) (II.0.5H2SO4), m. 222-5° (from H2O). II.0.5H2SO4 (3 g.) in 50 cc. H2O adjusted with NH4OH to pH 9 and allowed to stand 3 days deposited 1.1 g. II, m. 187-9° (from H2O). II.0.5H2SO4 (75 g.) and 200 cc. HCONH2 heated 45 min. at 180-90°, cooled, diluted with 1 l. cold H2O, and filtered yielded 48.0 g. 4-hydroxypyrazolo[3,4-d]pyrimidine (III). II.0.5H2SO4 (100 g.) and 200 g. urea heated 20 min. at 160° and then 20 min. at 190° and dissolved in hot dilute aqueous NaOH, the boiling basic solution carefully acidified with AcOH and filtered after 10 min. yielded 74 g. 90-5% pure 4,6-di-OH analog (IIIa) of III. I (35 g.) and 70 g. CS(NH2)2 heated 0.5 hr. at 180° and 10 min. at 200°, cooled, and dissolved in hot dilute aqueous NaOH, the hot solution treated with C, and the boiling filtrate carefully acidified with glacial AcOH yielded 26.0 g. 4-amino-6-mercaptopyrazolo[3,4-d]pyrimidine (IV), light tan material. II.0.5H2SO4 (50 g.) with 100 g. CS(NH2)2 gave similarly 24.0 g. 4-OH analog (V) of IV. Dry III (10 g.) added to 300 cc. POCl3, the mixture refluxed 1.5 hrs. with 30 cc. PhNMe2, the excess POCl3 removed in vacuo, the sirupy residue poured with stirring into 100 cc. H2O and 400 g. crushed ice and extracted with Et2O, and the extract worked up gave 9.8 g. 4-chloropyrazolo[3,4-d]pyrimidine (VI), decomposed at 130-5° (from C6H6). III (10 g.) finely powd. and mixture with 50 g. P2S5, the mixture added in small portions with stirring to 300 cc. Tetralin at 165° during 0.5 hr., the mixture heated 4 hrs. with stirring at 190-5°, cooled, and filtered, the filter residue washed with petr. ether, dried, added carefully to 1 l. H2O at 80°, boiled 10 min., and treated with enough KOH to effect solution, the solution stirred with C and filtered, and the hot filtrate acidified with AcOH gave 10.1 g. 4-mercaptopyrazolo[3,4-d]pyrimidine (VII), white crystals, m. above 360° (from 30% EtOH). VI (2 g.) and 2 g. CS(NH2)2 refluxed 2 hrs. with 100 cc. absolute EtOH cooled and filtered gave 1.6 g. crude VII. VI (3 g.) in 150 cc. concentrated NH4OH concentrated on the steam bath to 50 cc., diluted with 200 cc. concentrated NH4OH, concentrated on the steam bath to 150 cc., boiled with C, filtered, and cooled gave 0.85 g. 4-aminopyrazolo[3,4-d]pyrimidine (VIII), colorless needles. I (30 g.) boiled 0.5 hr. with 60 cc. HCONH2, cooled, diluted with 100 cc. cold H2O, and filtered, the residue suspended in 400 cc. hot H2O, treated with 50 cc. concentrated HCl, boiled 15 min. with C, and the hot filtrate adjusted to pH 8 with concentrated NH4OH and cooled to room temperature gave 21.0 g. VIII, colorless solid. VI (5.0 g.) and alc. NH3 heated 12 hrs. at 100° in a bomb and filtered, and the crude residue dissolved in dilute HCl and reprecipitated with NH4OH gave 3.9 g. VIII. IIIa (10 g.) and 30 cc. PhNMe2 refluxed 1 hr. with 250 cc. POCl3, the mixture worked up in the usual manner, and the product isolated with Et2O gave 2.4 g. compound C12H10ClN4(sic), light yellow needles, m. 225-7° (from xylene). V (14 g.) and 10 g. NaOH in 300 cc. H2O shaken 10 min. at 5° with 12 g. MeI, charcoaled, filtered, and acidified with AcOH yielded 12.0 g. 4-hydroxy-6-methylmercaptopyrazolo[3,4-d]pyrimidine (IX). I (10 g.) heated 20 min. with 20 g. urea at 180-200°, the cooled solid dissolved in 2N NaOH, the solution boiled gently 10 min. with C, and the boiling filtrate acidified with glacial AcOH gave 4-amino-6-hydroxypyrazolo[3,4-d]-pyrimidine which was purified by reprecipitation IX (22.0 g.), 400 cc. POCl3, and 30 cc. PhNMe2 refluxed 0.5 hr. gave 16 g. 4-Cl analog of IX, m. 178-9° (decomposition) (from heptane). VII (5 g.) in 65 cc. 0.8N NaOH shaken 15 min. at 20° with 5.0 g. MeI, treated with C, filtered, and acidified with AcOH, the crude precipitate suspended in 100 cc. H2O and adjusted with NH4OH to pH 9 and filtered, and the residue washed and recrystallized from H2O yielded 4.1 g. 4-MeS analog of VII, m. 193°. IIIa (15 g.) and 80 g. P2S5 refluxed 4 hrs. with 900 cc. dry pyridine and evaporated in vacuo on the steam bath, the residue diluted with 600 cc. ice H2O, allowed to stand 0.5 hr. at room temperature, heated 2 hrs. on the steam bath, the solution refrigerated overnight, and the crude precipitate reprecipitated with AcOH from boiling aqueous alkali gave 12.6 g. 4-mercapto-6-hydroxypyrazolo[3,4-d]pyrimidine, light green needles. V (15 g.) and 65 g. P2S5 in 900 cc. dry pyridine gave similarly 12.0 g. 4,6-dimercaptopyrazolo[3,4-d]pyrimidine, light green solid. Finely powd. VI (4.5 g.) in 150 cc. H2O and 4 cc. concentrated NH4OH hydrogenated about 6 hrs. at 20 lb. pressure over 1.0 g. 10% Pd-C and filtered, the residue extracted with 100 cc. boiling H2O, the combined filtrates evaporated to dryness on the steam bath, the residue extracted 18 hrs. with 200 cc. PhMe in a Soxhlet apparatus, the extract evaporated, and the residue sublimed at 180-200° and 15 mm. yielded 2.65 g. pyrazolo[3,4-d]pyrimidine (X), colorless needles, m. 213-14°. VI (3.0 g.) heated 1 hr. on the steam bath with 0.6 g. Na dissolved in 30 cc. absolute EtOH, diluted with 20 cc. H2O, and neutralized with AcOH gave 1.3 g. 4-EtO derivative of X, m. 168-9°. 4-Cl analog (XI) of X (7.0 g.) in 150 cc. EtOH and 10 cc. concentrated NH4OH hydrogenated 24 hrs. over 2.7 g. Pd-C at 20 lb. pressure, filtered, and evaporated to dryness on the steam bath yielded 1.7 g. 6-methylmercaptopyrazolo[3,4-d]pyrimidine, white crystals, m. 210-12° (from 80% EtOH). XI (4.0 g.) heated 4 hrs. on the steam bath with 1.0 g. Na in 75 cc. absolute MeOH, neutralized with glacial AcOH, and cooled gave 3.1 g. 4-MeO analog of IX, m. 193-4° (from aqueous MeOH). VI (5-10 g.) added to 50-100 cc. of a 25-40% aqueous solution of a primary or secondary amine, heated 4 hrs. on the steam bath, refrigerated overnight, and filtered, and the residue washed with a little ice water and recrystallized gave the corresponding N-substituted-4-aminopyrazolo[3,4-d]pyrimidines (XII) (method A); VI (5-10 g.) added to about 0.15 mole primary or secondary amine in 150 cc. absolute EtOH, heated 4 hrs. on the steam bath, cooled overnight and filtered, and the crude product recrystallized gave the corresponding XII (method B) (N-substituents, m.p., % yield, and method given): H, Me, 227-8° (from H2O), 83, A; Me, Me, 233-4° (from C6H6-EtOH), 61, A; Et, Et, 186-7° (from aqueous EtOH), 85, A; H, iso-Pr, 253-4° (from H2O), 70, A; H, Ph, 263-4° (from EtOH), 55, B; H, PhCH2, 215-17° (from aqueous EtOH), 78, B; H, Et, 259-60° (from aqueous EtOH), 77, A; H, 1-furylmethyl, 223-5° (from EtOH), 82, B; Me, Ph, 234-6° (from EtOH), 63, B; H, Bu, 205-6° (from aqueous EtOH), 75, B; H, o-MeC6H4, 260-1° (from EtOH), 85, B. XI gave similarly the 6-MeS derivatives of XII (N-substituents, m.p., % yield, and method given): H, H, above 300° (from H2O), 58, A; Me, Me, 263-5° (aqueous EtOH), 45, A; H, NH2, above 300° (from H2O), 30, A; H, (CH2)2NEt2, 130-2° (from EtOH), 35, B. The solubilities of a number of 4,6-disubstituted-pyrazolo[3,4-d]pyrimidines (XIII) are tabulated (4 and 6-substituents, and solubility in H2O at 100° in parts of H2O necessary to dissolve 1 part XIII given): OH, H, 190; OH, OH, 800; NH2, H, 1000; MeNH, H, 10; Me2N, H, 10; SH, H, 500; H, MeS, 350; MeS, H, 300; H, H, 200 (at 30°). The ultraviolet absorption maximum of the various XIII described at pH 1 and 11 are listed. The experimental process involved the reaction of 4-Chloro-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine(cas: 85426-79-5).Safety of 4-Chloro-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine

4-Chloro-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine(cas:85426-79-5) belongs to pyrazoles-derivatives. The use of pyrazole derivatives is based on their analgesic, anti-inflammatory, antipyretic, antiarrhythmic, sedative, muscle relaxant, neuroleptic, anticonvulsant, monoamine oxidase inhibitory, antidiabetic and antibacterial activities.Safety of 4-Chloro-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Chen, Yuzhong et al. published their patent in 2021 |CAS: 1187582-58-6

The Article related to bromochloropyridinylpyrazolecarboxylic acid preparation intermediate, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.SDS of cas: 1187582-58-6

On April 22, 2021, Chen, Yuzhong; Freudenberger, John Herbert; Wright, James published a patent.SDS of cas: 1187582-58-6 The title of the patent was Methods for the preparation of 5-bromo-2-(3-chloropyridin-2-yl)-2H-pyrazole-3-carboxylic acid. And the patent contained the following:

Described herein are novel methods of synthesizing 5-bromo-2-(3-chloro-pyridin-2-yl)-2H-pyrazole-3-carboxylic acid from pyrazole or pyrazole derivatives For example, protecting pyrazole with 3,4-dihydro-2H-pyrazole followed by bromination of the resulting 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole, deprotecting (5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole containing 3-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole), coupling 3-bromo-1H-pyrazole with 2,3-dichloropyridine, and reacting 2-(3-bromo-1H-pyrazol-1-yl)-3-chloropyridine with CO2 in the presence of TMPMgCl.LiCl solution in THF afforded 5-bromo-2-(3-chloro-pyridin-2-yl)-2H-pyrazole-3-carboxylic acid. General method of preparing compound I [each of R5-R10 = (independently) H and halo; and R13 = an organic acid], starting by halogenation of protected pyrazole II [R14 = (un)substituted carbocycle and heterocycle], was disclosed. The experimental process involved the reaction of 5-Bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole(cas: 1187582-58-6).SDS of cas: 1187582-58-6

The Article related to bromochloropyridinylpyrazolecarboxylic acid preparation intermediate, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.SDS of cas: 1187582-58-6

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Blake, James et al. published their patent in 2009 |CAS: 924909-16-0

The Article related to pyrazolopyridine derivative preparation chk1 chk2 kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Computed Properties of 924909-16-0

On July 16, 2009, Blake, James; Gunawardana, Indrani W.; Le Huerou, Yvan; Mohr, Peter J.; Wallace, Eli M.; Wang, Bin published a patent.Computed Properties of 924909-16-0 The title of the patent was Pyrazolopyridine derivatives and their pharmaceutical compositions as CHK1 and CHK2 kinase inhibitors for the treatment of various diseases and preparation thereof. And the patent contained the following:

Title compounds I and II, their pharmaceutical compositions, and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of CHK1 and CHK2 kinases and useful in the treatment of diseases mediated by said kinases. Compounds of formula I [m, n, p independently = 0 or 1; G = (un)substituted Ph when m = 1, or G = absent, alkyl, or (un)substituted Ph when m = 0; R1 = H, alkyl, haloalkyl, etc.; R2 = H, CF3, (un)substituted alkenyl, etc., with the provision that when R1 = H, then R2 = OR14; R14 = alkyl optionally substituted with 1 or more OH; R3, R7, and R8 independently = H or alkyl; R5, R6, and R9 independently = H or Me] and II [Q = CH2 or CH2CH2; R15 and R16 independently = H or alkyl], their pharmaceutical compositions, and their pharmaceutically acceptable salts, are claimed. For example, compound III·2HCl was prepared via amidation of (S)-3-(tert-butoxycarbonyl(isopropyl)amino)-2-(4-chlorophenyl)propanoic acid with 5-phenyl-4-(piperazin-1-yl)-1H-pyrazolo[3,4-b]pyridine dihydrochloride, followed by removal of the BOC protecting group. Select I and II were assayed for CHK1 kinase activity and found to possess IC50 values of <10 μM. The experimental process involved the reaction of 1-(4-Methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol(cas: 924909-16-0).Computed Properties of 924909-16-0

The Article related to pyrazolopyridine derivative preparation chk1 chk2 kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Computed Properties of 924909-16-0

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Sun, Liangpeng et al. published their patent in 2019 |CAS: 36640-53-6

The Article related to diarylpyrazole carboxyalkyl rhodamine preparation ptp1b inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Recommanded Product: 36640-53-6

On May 21, 2019, Sun, Liangpeng; Piao, Huri; Xu, Lili published a patent.Recommanded Product: 36640-53-6 The title of the patent was 1,3-Diarylpyrazole PTP1B inhibitor containing carboxyalkyl rhodamine structure and preparation and application thereof. And the patent contained the following:

The invention provides a compound of 1,3-diarylpyrazole PTP1B inhibitor containing carboxyalkyl rhodamine structure as shown in the formula or a pharmaceutically acceptable salt thereof as a novel protein tyrosine phosphatase 1B (PTP1B) inhibitor. Studies show that the inhibitor can effectively inhibit the activity of PTP1B and can be used as an insulin sensitizer for preventing and/or treating diseases related to insulin resistance mediated by PTP1B, particularly type II diabetes and obesity. The invention also provides a preparation method of the inhibitor. The experimental process involved the reaction of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde(cas: 36640-53-6).Recommanded Product: 36640-53-6

The Article related to diarylpyrazole carboxyalkyl rhodamine preparation ptp1b inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Recommanded Product: 36640-53-6

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Rainer, Georg et al. published their patent in 1972 |CAS: 36640-53-6

The Article related to pyrazolecarboxaldehyde, hydroxymethylpyrazole, benzenes pyrazolyl, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Formula: C20H14N2O

On February 24, 1972, Rainer, Georg; Riedel, Richard published a patent.Formula: C20H14N2O The title of the patent was 4-(Hydroxymethyl)- and 4-formyl-1-arylpyrazoles. And the patent contained the following:

Thirty title compounds [I, R = CHO or CH2OH; R1 = (substituted) phenyl, 3-pyridyl, 2-furyl, or 2-naphthyl; R2 = H, F, Cl, Br, Me, or MeO], useful as intermediates for pharmaceutical 4-(carboxymethyl)- or 4-(cyanomethyl)-1-arylpyrazoles, were prepared by reacting R1CMe:NNHC6H4R2-p with DMF and POCl3 via I (R = CH:N+Me2ClO4-) (Ia). Saponifying Ia gave I (R = CHO), which on reduction gave I (R = CH2OH). Thus, POCl3 was stirred 1 hr with DMF and treated with p-ClC6H4CMe:NNHPh 6 hr at 70°. The mixture was treated 5 hr with aqueous NaOH at pH 7 to give 99% I (R = CHO, R1 = C6H4Cl-p, R2 = H) (II). II was treated in EtOH and DMF with NaBH4 1 hr at 20-5° to give 93% I (R = CH2OH, R1 = C6H4Cl-p, R2 = H). The experimental process involved the reaction of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde(cas: 36640-53-6).Formula: C20H14N2O

The Article related to pyrazolecarboxaldehyde, hydroxymethylpyrazole, benzenes pyrazolyl, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Formula: C20H14N2O

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Wang, Renxiao et al. published their patent in 2020 |CAS: 36640-53-6

The Article related to phenyl pyrazole preparation bcl inhibitor treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Application of 36640-53-6

On February 4, 2020, Wang, Renxiao; Liu, Hong; Yu, Biao; Li, Yangfeng; Li, Chunpiao; Li, Yan; Zhou, Mi; Li, Qing; Su, Minyi published a patent.Application of 36640-53-6 The title of the patent was Phenyl pyrazole compound, its pharmaceutical composition, preparing method and application. And the patent contained the following:

The invention relates to Ph pyrazole compounds of formula I and II, their preparation and application as Bcl inhibitor. Compounds I and II, wherein Ra is R1(O)n(CH2)m; R1 is C6-14 aryl or substituted C6-14 aryl; m is 0-6; n is 0 or 1; R is H or C1-C4 alkyl; Rb and Rc are independently H, C3-C8 cycloalkyl, C1-C6 alkyl, etc.; their stereoisomers, or pharmaceutically acceptable salts, are claimed. The inventive compound can be applied in preparing the drugs for preventing and/or treating Bcl-related diseases or preparing Bcl inhibitor, with high activity and low toxicity. The experimental process involved the reaction of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde(cas: 36640-53-6).Application of 36640-53-6

The Article related to phenyl pyrazole preparation bcl inhibitor treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Application of 36640-53-6

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics